Single Nucleotide Polymorphism (SNP) Genotyping Market Size, Share and Trends 2025 to 2034

Revenue, 2024

USD 6.21 Bn

Forecast Year, 2034

USD 42.12 Bn

CAGR, 2025 - 2034

21.10%

Report Coverage

Global

What is the Single Nucleotide Polymorphism (SNP) Genotyping Market Size?

The global single nucleotide polymorphism (SNP) genotyping market size accounted for USD 7.52 billion in 2025 and is predicted to increase from USD 9.11 billion in 2026 to approximately USD 42.12 billion by 2034, expanding at a CAGR of 21.10% from 2025 to 2034. The market is rapidly expanding due to advancements in genomic technology, the rise in fatal and chronic diseases, the expansion of SNP genotyping applications, and substantial government funding for R&D in the pharma and biotech sectors worldwide.

Market Highlights

• North America accounted for the largest market share of 46.4% in 2024.
• The Asia Pacific is expected to witness the highest CAGR from 2025 to 2034.
• By technology, the PCR-based genotyping segment held the largest market share of 40.4% in 2024.
• By technology, the next-generation sequencing-based genotyping segment is growing at a solid CAGR from 2025 to 2034.
• By product/component, the instruments segment held the major market share of 61.4% in 2024.
• By product, the software & services segment is expected to grow the highest CAGR of 13.2% from 2025 to 2034.
• By application, the pharmaceuticals & pharmacogenomics segment contributed the highest market share of 38.4% in 2024.
• By application, the genetic testing/diagnostics segment is growing at a strong CAGR of 12.8% from 2025 to 2034.
• By end user, the pharmaceutical & biotechnology companies segment captured the biggest market share of 51.5% in 2024.
• By end user, the contract research organizations (CROs) / service providers segment is expected to expand at a notable CAGR of 12.5% from 2025 to 2034.

Single Nucleotide Polymorphism (SNP) Genotyping Market Means

The Single Nucleotide Polymorphism (SNP) Genotyping Market refers to the ecosystem of technologies, instruments, reagents, software , and services used to identify and analyse individual base-pair variations (SNPs) in DNA across populations, organisms, and disease states.

These technologies enable high-throughput genotyping for clinical diagnostics, pharmacogenomics , agricultural biotechnology , and research applications, supporting precision medicine , biomarker discovery, and trait selection in crops & livestock. The market covers hardware platforms (arrays, PCR, NGS), consumables, bioinformatics tools, and associated services.

AI Shifts in Single Nucleotide Polymorphism (SNP) Genotyping Market

The integration of AI will be revolutionary in the SNP Genotyping market, enabling more accurate and efficient variant calling from large genomic datasets and accelerating research while supporting personalized medicine . Models like ML and deep learning help identify disease-linked SNPs and predict disease risk prior to treatment, further accelerating drug development.

With the help of suboptimal DNA samples and streamlined processes, AI optimizes genotyping and makes complex genetic processes more accessible, enabling more accurate analysis. This will help tailor medical treatments to the type of disease and improve outcomes, and reduce mortality rates.

Single Nucleotide Polymorphism (SNP) Genotyping Market Outlook

[[market_outlook]]

Market Scope

Single Nucleotide Polymorphism (SNP) Genotyping Market Segmental Insights

[[segment_insights]]

Single Nucleotide Polymorphism (SNP) Genotyping Market Regional Insights

[[regional_insights]]

Single Nucleotide Polymorphism (SNP) Genotyping Market Value Chain

Single Nucleotide Polymorphism (SNP) Genotyping Market Companies

[[market_company]]

Other Key Players in the Market for Single Nucleotide Polymorphism (SNP) Genotyping

• QIAGEN N.V. : QIAGEN delivers advanced sample preparation, PCR, and genotyping kits designed for SNP analysis. Its platforms, such as QIAseq and Rotor-Gene Q, enable high-precision detection of genetic variants for research and clinical applications in oncology , pharmacogenomics, and infectious disease.
• Bio-Rad Laboratories , Inc.: Bio-Rad provides SNP genotyping assays and instrumentation, including droplet digital PCR (ddPCR) and real-time PCR platforms. The company genotyping technologies are widely used in biomarker validation, agricultural genetics, and molecular diagnostics .
• Danaher Corporation: Danaher, through subsidiaries such as Cepheid and Beckman Coulter, offers genomic analysis systems and reagents used in SNP genotyping. Its technologies support precision medicine, genomic research, and high-throughput screening for genetic variation.
• Beckman Coulter, Inc.: Beckman Coulter provides high-performance liquid handling and analytical systems that support SNP genotyping workflows. Its automated platforms improve accuracy and efficiency in sample preparation, genotyping, and data analysis for research and diagnostics.
• Luminex Corporation: Luminex offers multiplex genotyping solutions using xMAP technology, enabling simultaneous analysis of multiple SNPs in a single reaction. The companys assays are used in pharmacogenomics, genetic research, and clinical diagnostics for complex trait analysis.
• PerkinElmer, Inc.: PerkinElmer provides molecular biology instruments and reagents for SNP genotyping, including PCR-based assays and genotyping arrays. Its genomic solutions are used across agriculture, human health, and environmental studies for genetic variation detection.
• Fluidigm Corporation: Fluidigm delivers microfluidic-based SNP genotyping systems designed for high-throughput genetic screening. Its IFC (Integrated Fluidic Circuit) technology enables efficient, cost-effective genotyping and variant analysis across large sample sets.
• Affymetrix (now part of Thermo Fisher Scientific): Affymetrix, integrated under Thermo Fisher, provides high-density SNP genotyping arrays and genomic analysis tools. Its platforms are widely used for population genetics, disease association studies, and precision medicine applications.
• Sequenom, Inc.: Sequenom, now incorporated into Laboratory Corporation of America (Labcorp), developed mass spectrometry-based genotyping solutions such as the MassARRAY system. The technology remains widely recognized for its accuracy in SNP and mutation analysis.
• Oxford Nanopore Technologies, Inc.: Oxford Nanopore offers long-read sequencing technology capable of detecting SNPs and structural variants in real time. Its portable and high-throughput sequencing platforms enable comprehensive genomic variation analysis for research and clinical applications.
• Promega Corporation: Promega provides molecular biology reagents and genotyping tools, including PCR and DNA quantification kits suitable for SNP detection. The companys solutions are used in genetic identification, forensic analysis, and biomedical research.

Single Nucleotide Polymorphism (SNP) Genotyping MarketSegments Covered in the Report

[[segment_covered]]